New drug candidate AH-008 takes first step toward easing chemotherapy nerve pain
Knowledge-focused
Recruiting now
This early-stage trial tests the safety and tolerability of a single dose of AH-008, a potential treatment for chemotherapy-induced peripheral neuropathy (nerve damage). Healthy adults aged 18 to 65 receive either AH-008 or a placebo by intravenous infusion. The study monitors si…
Phase: PHASE1 • Sponsor: AnHorn Medicines Co. Ltd. • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC